CSIMarket
 

Azenta Inc   (NASDAQ: AZTA)

Azenta Inc 's

Competitiveness




 

AZTA Sales vs. its Competitors Q2 2026



Comparing the current results to its competitors, Azenta Inc reported Revenue increase in the 2 quarter 2026 by 0.8 % year on year.
The revenue growth was below Azenta Inc 's competitors' average revenue growth of 6.26 %, achieved in the same quarter.

List of AZTA Competitors





Revenue Growth Comparisons




Net Income Comparison


Azenta Inc , despite income growth by most of its competitors recorded a net loss, despite income increase by most of its competitors of 1.49 %

<<  AZTA Stock Performance Comparisons



  

Overall company Market Share Q2 2026

With modest revenue growth of 0.8 % within Overall company, Azenta Inc failed to increase sales with the same pace, like most of company's peers within this division.
<<  More on AZTA Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Azenta Inc




Karyopharm Therapeutics Inc
Share Performance



-75.60%
One Year



Karyopharm Therapeutics Inc
Profile

Karyopharm Therapeutics Inc's business model revolves around developing and commercializing novel therapeutic products to treat various types of cancers and other diseases.

More about Karyopharm Therapeutics Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 46.880 mill. $ 146.621 mill. $ -224.740 mill.


Thermo Fisher Scientific Inc
Share Performance



-0.30%
30 Days



Thermo Fisher Scientific Inc
Profile

Thermo Fisher Scientific Inc operates as a global leader in scientific research and services by delivering an extensive range of high-quality scientific instruments, reagents, consumables, and software solutions tailored to industries such as healthcare, pharmaceuticals, biotechnology, academia, and government. The company enhances its value proposition through a comprehensive suite of services, including laboratory outsourcing, scientific consulting, and data analysis, which help streamline research and development processes for its customers. By leveraging advanced technology and deep industry expertise, Thermo Fisher empowers researchers and organizations to drive innovation and accelerate scientific discovery.

More about Thermo Fisher Scientific Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 223,779.780 mill. $ 46,336.000 mill. $ 6,989.000 mill.


Twist Bioscience Corporation
Share Performance



+291.63%
This Year



Twist Bioscience Corporation
Profile

Twist Bioscience Corporation operates as a biotechnology company that focuses on synthetic DNA manufacturing. Its business model consists of providing customers with custom DNA synthesis, gene libraries, and specialty components. This includes offering a variety of products and services tailored to meet the specific needs of researchers and biotech companies, enabling them to accelerate their development of personalized medicines, agricultural biotechnology, and more.

More about Twist Bioscience Corporation's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 7,826.899 mill. $ 409.479 mill. $ -81.276 mill.

Sources: Azenta Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Azenta Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.